Skip to main content
MDGL
NASDAQ Life Sciences

Madrigal 10-Q Details First Profitable Quarter, $961.8M Cash, EPS Restatement and New SOX Suit

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$428.01
Mkt Cap
$9.961B
52W Low
$399
52W High
$615
52W Position info
7.3% above low
Off High info
30% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

MDGL is trading near its 52-week low of $399 (7.3% above the low) on elevated volume (1.8× avg).

Summary

Madrigal's 10-Q confirms the first profitable quarter ($55.4 million net income on $431.3 million of Rezdiffra sales) already reported this morning, and adds $961.8 million of cash, a restated EPS presentation, and disclosure of a new SOX whistleblower lawsuit filed October 9, 2026.


Key Events · Earnings and Guidance · MDGL

  • First Profitable Quarter Confirmed

    Q3 2026 product revenue of $431.3 million versus $287.3 million a year earlier (+50%), producing $55.4 million of net income and $1.83 diluted EPS — the company's first profitable quarter.

  • Cash Position and Debt Terms

    Cash, cash equivalents, restricted cash and marketable securities totaled $961.8 million at September 30, 2026, against $350.0 million outstanding on the Blue Owl term loan at an 8.48% rate and a $100.0 million minimum unrestricted cash covenant; the company says liquidity funds operations past one year.

  • EPS Presentation Restated

    Pre-Funded Warrants and Series A/B Preferred are now included in basic and diluted share counts, revising FY2025 net loss per share to $(10.15) from $(12.85) and the nine months ended 9/30/25 to $(8.12) from $(10.32); management deemed the change immaterial.

  • New Whistleblower Lawsuit Disclosed

    A former employee filed Charlton v. Madrigal Pharmaceuticals, Inc. on October 9, 2026 in the Northern District of Illinois, alleging SOX retaliation over internal concerns about data and reporting practices; the company disputes the claims and plans to defend.


Analysis · MDGL · Life Sciences

The headline numbers — $431.3 million of Q3 Rezdiffra sales and $55.4 million of net income, or $1.83 diluted EPS — were already out via this morning's 8-K, so the print itself is not new. What the 10-Q adds is the balance sheet behind it: $961.8 million of cash, equivalents and marketable securities at September 30, 2026, against a $350.0 million term loan at 8.48% and a $100.0 million minimum-cash covenant, which puts the company well past the financing risk that dominated its loss-making years. Two items deserve attention. First, the company revised its earnings-per-share presentation to fold the Pre-Funded Warrants and Series A/B Preferred into basic and diluted share counts, cutting previously reported per-share losses (FY2025 goes from $(12.85) to $(10.15)); management judged the change immaterial, but it changes the share base investors should use. Second, a former employee sued on October 9, 2026 under the Sarbanes-Oxley whistleblower provisions, alleging retaliation after raising internal concerns about data and reporting practices — the company disputes it and no reserve is recorded. The nine-month picture is still a $96.9 million net loss on a $2,187.4 million accumulated deficit, so one profitable quarter does not yet make a trend.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MDGL was trading at $428.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $399.00 to $615.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MDGL - Latest Insights

MDGL
Nov 06, 2026, 5:30 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $399.93
Real-time Price: $425.45 info
Change: +$25.51 (+6%) info
Market Cap: $9.879B info
MDGL
Nov 05, 2026, 10:35 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $408.99
Real-time Price: $425.45 info
Change: +$16.45 (+4%) info
Market Cap: $9.879B info
MDGL
Nov 03, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $477.00
Real-time Price: $425.45 info
Change: -$51.56 (-11%) info
Market Cap: $9.879B info
MDGL
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $431.16
Real-time Price: $425.45 info
Change: -$5.71 (-1%) info
Market Cap: $9.879B info
MDGL
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $475.00
Real-time Price: $425.45 info
Change: -$49.56 (-10%) info
Market Cap: $9.879B info